Drug Repurposing: Considerations for Selection Criteria and Prioritization

Hybrid Public Meeting
Wednesday, August 5, 2026
10:30 am – 5 pm ET

Agenda

10:30 am Welcome
- Susan C. Winckler, RPh, Esq, CEO, Reagan-Udall Foundation for the FDA

10:35 am Opening Remarks
- Brian Fahey, Senior Advisor, Immediate Office of the Commissioner, FDA

10:40 am FDA's Drug Repurposing Efforts
- Marta Sokolowska, PhD, Deputy Center Director for Substance Use and Behavioral Health - Center for Drug Evaluation and Research (CDER), FDA

10:50 am Session 1: Snapshots of Repurposing Efforts
- Mitra Ahadpour, MD, Deputy Director, Office of Translational Sciences, CDER, FDA
- Matt Hall, PhD, Scientific Director, National Center for Advancing Translational Sciences
- Heather Stone, MPH, Health Science Policy Analyst, Office of Medical Policy, CDER, FDA

11:15 am Session 2: Selection Criteria and Prioritization
- Caroline Huang, PhD, Supervisory General Health Scientist, Controlled Substances Initiatives, CDER, FDA

Reactor Panel:
- Susan Cantrell, RPh, MHL, Academy of Managed Care Pharmacy
- Emily Einstein, PhD, Senior Director, Quality and Science, American Society of Addiction Medicine
- Pam Gavin, MBA, CEO, National Organization for Rare Diseases
- Huong Huynh, PhD, Director of Regulatory Science, Critical Path Institute
- Janet Woodcock, MD, Former FDA Acting Commissioner

12:15 pm Break for Lunch
Lunch on your own. A list of local eateries will be available.

1:15 pm Session 3: Evidence and Submission Expectations

- Sundeep Agrawal, MD, Associate Director of Clinical Programs, Oncology Center of Excellence, FDA
- David Fajgenbaum, MD, MSc, Co-Founder and President, Every Cure

Reactor Panel:

- Amy Abernethy MD, PhD, CEO, Highlander Health
- Marie Bradley, PhD, MPharm, Senior Advisor, Office of Medical Policy, CDER, FDA
- Emily Freilich, MD, Division Director, Division of Neurology, Office of New Drugs, CDER, FDA
- Donald Lo, PhD, Director of Medicines Development and Scientific Lead, REMEDi4ALL

2:15 pm Session 4: Federal Partner Discussion

Panelists:

- Andrew Brack, PhD, Program Manager, Proactive Health Office, ARPA-H
- Christine Colvis, PhD, Director, Office of Drug Development Partnership Programs, National Center for Advancing Translational Sciences
- Shari Ling, MD, CMS Deputy Chief Medical Officer, Centers for Medicare and Medicaid Services
- Marta Sokolowska, PhD, Deputy Center Director for Substance Use and Behavioral Health, CDER, FDA
- Danielle Turley, PhD, Acting Director, Division of Regulatory & Quality Affairs, BARDA

3:15 pm Public Comment

- Individuals who registered in advance to provide public comment will have 2.5 minutes for remarks.
- No direct questions will be posed to speakers or panelists.

5 pm Adjourn

This project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of an award of $118,960 in federal funds (100% of the project). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA, HHS, or the U.S. Government. For more information, please visit FDA.gov